NASDAQ:DBVT

DBV Technologies (DBVT) Stock Price, News & Analysis

DBV Technologies logo
$10.27 -0.75 (-6.81%)
Closing price 04:00 PM Eastern
Extended Trading
$10.26 -0.01 (-0.10%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About DBV Technologies Stock (NASDAQ:DBVT)

Advanced

Key Stats

Today's Range
$10.19
▼
$10.99
50-Day Range
$8.87
▼
$13.44
52-Week Range
$8.63
▼
$26.18
Volume
142,685 shs
Average Volume
410,693 shs
Market Capitalization
$645.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$45.25
Consensus Rating
Moderate Buy

Company Overview

DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. Founded in France, the company’s research centers on epicutaneous immunotherapy, an approach that delivers small amounts of an allergen through the skin using a patch.

Its lead investigational program is Viaskin Peanut, a patch-based treatment being developed for peanut allergy. DBV has also conducted research into treatments for other conditions, including milk allergy and eosinophilic esophagitis. Its product candidates are investigational and are not approved treatments.

DBV Technologies is headquartered in France and has operations in the United States. The company’s shares trade on Nasdaq under the symbol DBVT and on Euronext Paris.

AI Generated. May Contain Errors.

DBV Technologies Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
77th Percentile Overall Score

DBVT MarketRank™: 
3.8667373162 of 5 stars

DBV Technologies scored higher than 77% of companies evaluated by MarketBeat, and ranked 111th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    DBV Technologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    DBV Technologies has a consensus price target of $45.25, representing about 340.6% upside from its current price of $10.27.

  • Amount of Analyst Coverage

    DBV Technologies has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about DBV Technologies' stock forecast and price target.
  • Earnings Growth

    Earnings for DBV Technologies are expected to grow in the coming year, from ($2.22) to ($1.90) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of DBV Technologies is -3.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of DBV Technologies is -3.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    DBV Technologies has a P/B Ratio of 2.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.30% of the float of DBV Technologies has been sold short.
  • Short Interest Ratio / Days to Cover

    DBV Technologies has a short interest ratio ("days to cover") of 1.67, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in DBV Technologies has recently decreased by 7.50%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    DBV Technologies does not currently pay a dividend.

  • Dividend Growth

    DBV Technologies does not have a long track record of dividend growth.

  • News Sentiment

    DBV Technologies has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for DBV Technologies this week, compared to 3 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, DBV Technologies insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    1.06% of the stock of DBV Technologies is held by insiders.

  • Percentage Held by Institutions

    71.74% of the stock of DBV Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about DBV Technologies' insider trading history.
Receive DBVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DBV Technologies and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

DBVT Stock News Headlines

Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
DBV Technologies S.A. ADR
See More Headlines

DBVT Stock Analysis - Frequently Asked Questions

DBV Technologies' stock was trading at $19.17 at the start of the year. Since then, DBVT stock has decreased by 46.4% and is now trading at $10.27.

DBV Technologies S.A. (NASDAQ:DBVT) issued its earnings results on Wednesday, October, 28th. The company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.29) by $0.41. The firm earned $1.60 million during the quarter, compared to analyst estimates of $558 thousand. DBV Technologies had a negative net margin of 5,392.17% and a negative trailing twelve-month return on equity of 120.95%.
Read the conference call transcript
.

Shares of DBV Technologies reverse split on the morning of Friday, November 29th 2024.The 1-5 reverse split was announced on Monday, November 11th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 28th 2024. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

DBV Technologies (DBVT) raised $93 million in an IPO on Wednesday, October 22nd 2014. The company issued 4,277,826 shares at a price of $21.64 per share.

Top institutional shareholders of DBV Technologies include Russell Investments Group Ltd. (0.13%), Cetera Investment Advisers (0.04%), China Universal Asset Management Co. Ltd. and Vontobel Holding Ltd. (0.02%). Insiders that own company stock include Bpifrance Epic, Pharis Mohideen and Adora Ndu.
View institutional ownership trends
.

Shares of DBVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that DBV Technologies investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Alibaba Group (BABA), Bristol Myers Squibb (BMY), Salesforce (CRM), Pfizer (PFE) and Gilead Sciences (GILD).

Company Calendar

Last Earnings
10/28/2026
Today
11/16/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:DBVT
CIK
1613780
Employees
125
Year Founded
2002

Price Target and Rating

High Price Target
$48.00
Low Price Target
$40.00
Potential Upside/Downside
+340.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.01)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$146.95 million
Net Margins
-5,392.17%
Pretax Margin
-5,361.66%
Return on Equity
-120.95%
Return on Assets
-88.35%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.24
Quick Ratio
3.24

Sales & Book Value

Annual Sales
$5.64 million
Price / Sales
114.50
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.36 per share
Price / Book
4.35

Miscellaneous

Outstanding Shares
62,880,000
Free Float
62,211,000
Market Cap
$645.78 million
Optionable
Optionable
Beta
-0.84

Social Links

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

This page (NASDAQ:DBVT) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners